Bio-Rad Laboratories, Inc. BIO.B Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Clinical Diagnostics | $1.57B+0.4% | $1.56B+2.1% | $1.53B+0.2% | $1.53B+0.1% | $1.53B-0.8% | |
| Life Science | $1.02B0.0% | $1.02B-0.7% | $1.03B+0.1% | $1.03B+1.2% | $1.02B-1.3% | |
| Gross Profit by Business | ||||||
| Clinical Diagnostics | $791M+0.5% | $786.8M+3.8% | $757.8M-1.1% | $766.3M-1.7% | $779.8M-2.1% | |
| Life Science | $552.3M-0.1% | $553.1M-4.4% | $578.8M-0.7% | $582.8M+0.6% | $579.1M-0.6% | |
| Total Assets by Business | ||||||
| Clinical Diagnostics | $1.88B-0.7% | $1.89B-1.1% | $1.92B-1.4% | $1.94B-0.3% | $1.95B-0.5% | |
| Life Science | $1.21B-0.5% | $1.22B+0.2% | $1.22B+0.5% | $1.21B+0.1% | $1.21B+1.4% | |
| Cost of goods sold by Business | ||||||
| Clinical Diagnostics | $777.9M+0.3% | $775.3M+0.5% | $771.5M+1.4% | $760.6M+1.9% | $746.3M+0.7% | |
| Life Science | $468.7M+0.1% | $468M+4.1% | $449.4M+1.1% | $444.5M+2.0% | $435.9M-2.2% | |
| Depreciation, Depletion and Amortization by Business | ||||||
| Clinical Diagnostics | $91.9M+1.7% | $90.4M+1.2% | $89.3M+2.4% | $87.2M+3.2% | $84.5M+0.4% | |
| Life Science | $76.3M+1.7% | $75M+3.0% | $72.8M+4.6% | $69.6M+2.2% | $68.1M+1.0% | |
| Goodwill by Business | ||||||
| Clinical Diagnostics | $1.69B+0.3% | $1.68B+0.6% | $1.67B+0.2% | $1.67B+0.5% | $1.66B+0.1% | |
| Life Science | $1.97B+8.7% | $1.81B+9.7% | $1.65B+10.7% | $1.5B+12.1% | $1.33B0.0% | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | ||||||
| Clinical Diagnostics | $6M-40.6% | $10.1M+120% | $4.6M-39.5% | $7.6M+322% | $1.8M+158% | |
| Goodwill, Impaired, Accumulated Impairment Loss by Business | ||||||
| Clinical Diagnostics | $1.17B0.0% | $1.17B0.0% | $1.17B0.0% | $1.17B0.0% | $1.17B0.0% | |
| Life Science | $167.2M0.0% | $167.2M0.0% | $167.2M0.0% | $167.2M0.0% | $167.2M0.0% | |
| Goodwill, net by Business | ||||||
| Clinical Diagnostics | $512.5M+1.0% | $507.2M+1.9% | $497.8M+0.8% | $493.9M+1.6% | $486.3M+0.4% | |
| Life Science | $1.8B+9.5% | $1.65B+10.7% | $1.49B+12.0% | $1.33B+13.9% | $1.17B0.0% | |
| Goodwill, Period Increase (Decrease) by Business | ||||||
| Clinical Diagnostics | $6M-40.6% | $10.1M+120% | $4.6M-39.5% | $7.6M+322% | $1.8M+158% | |
| Life Science | $159.4M-1.7% | $162.1M+0.1% | $161.9M0.0% | $161.9M— | $0— | |
| Net Sales by Geography | ||||||
| Americas | $170.7M+3.2% | $165.4M+2.1% | $162M-0.7% | $163.1M-3.3% | $168.6M-0.4% | |
| Asia Pacific | $519.6M+1.2% | $513.3M+3.1% | $497.9M-1.2% | $503.8M-0.9% | $508.6M-2.5% | |
| Europe | $888.8M+0.8% | $881.8M+2.4% | $860.9M+2.0% | $844.4M+1.3% | $833.7M0.0% | |
| UNITED STATES | $1.01B-1.2% | $1.02B-1.4% | $1.04B-0.6% | $1.04B+1.2% | $1.03B-1.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bio-Rad Laboratories, Inc. break its business down?
- Bio-Rad Laboratories, Inc. (BIO.B) reports net sales by business across 3 parts — All Other Segments, Clinical Diagnostics and Life Science. Each is extracted from the segment footnotes and tracked over time.
- Where does Bio-Rad Laboratories, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bio-Rad Laboratories, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
